These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31125338)

  • 21. The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review.
    Bayoumy AB; Simsek M; Seinen ML; Mulder CJJ; Ansari A; Peters GJ; De Boer NK
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):111-123. PubMed ID: 32090622
    [No Abstract]   [Full Text] [Related]  

  • 22. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study.
    Pavlidis P; Ansari A; Duley J; Oancea I; Florin T
    Inflamm Bowel Dis; 2014 Dec; 20(12):2239-46. PubMed ID: 25230165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
    Musumba CO
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1025-37. PubMed ID: 24099468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity.
    Oancea I; Png CW; Das I; Lourie R; Winkler IG; Eri R; Subramaniam N; Jinnah HA; McWhinney BC; Levesque JP; McGuckin MA; Duley JA; Florin TH
    Gut; 2013 Apr; 62(4):594-605. PubMed ID: 22773547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic hepatotoxicity following 6-thioguanine therapy for childhood acute lymphoblastic leukaemia.
    Piel B; Vaidya S; Lancaster D; Taj M; Pritchard-Jones K
    Br J Haematol; 2004 May; 125(3):410-1; author reply 412. PubMed ID: 15086428
    [No Abstract]   [Full Text] [Related]  

  • 26. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice.
    Seinen ML; van Asseldonk DP; Mulder CJ; de Boer NK
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):291-4. PubMed ID: 20922194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review.
    Gisbert JP; González-Lama Y; Maté J
    Am J Gastroenterol; 2007 Jul; 102(7):1518-27. PubMed ID: 17391318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thioguanine versus mercaptopurine in childhood ALL.
    Stanulla M; Schünemann HJ
    Lancet; 2006 Oct; 368(9544):1304-6. PubMed ID: 17046444
    [No Abstract]   [Full Text] [Related]  

  • 29. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.
    Stoneham S; Lennard L; Coen P; Lilleyman J; Saha V
    Br J Haematol; 2003 Oct; 123(1):100-2. PubMed ID: 14510948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.
    Geller SA; Dubinsky MC; Poordad FF; Vasiliauskas EA; Cohen AH; Abreu MT; Tran T; Martin P; Vierling JM; Targan SR
    Am J Surg Pathol; 2004 Sep; 28(9):1204-11. PubMed ID: 15316320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a role for thioguanine therapy in IBD in 2017 and beyond?
    Taylor KM; Ward MG; Blaker PA; Sparrow MP
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):473-486. PubMed ID: 28276819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
    Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
    Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia.
    Toksvang LN; Grell K; Nielsen SN; Nersting J; Murdy D; Moorman AV; Vora A; Schmiegelow K
    Leukemia; 2022 Feb; 36(2):555-557. PubMed ID: 34535761
    [No Abstract]   [Full Text] [Related]  

  • 34. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?
    Derijks LJ; Gilissen LP; de Boer NK; Mulder CJ
    J Hepatol; 2006 Apr; 44(4):821-2. PubMed ID: 16487623
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review.
    Meijer B; Mulder CJ; Peters GJ; van Bodegraven AA; de Boer NK
    World J Gastroenterol; 2016 Oct; 22(40):9012-9021. PubMed ID: 27833392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy.
    Seinen ML; van Asseldonk DP; de Boer NK; Bouma G; van Nieuwkerk CM; Mulder CJ; Bloemena E; van Bodegraven AA
    Inflamm Bowel Dis; 2017 Mar; 23(3):448-452. PubMed ID: 28151736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease - A comprehensive narrative review.
    Pugliese N; Giuli L; Mastrorocco E; Santopaolo F; Marcozzi G; Bezzio C; Dal Buono A; Gabbiadini R; Gasbarrini A; Ponziani FR; Armuzzi A; Aghemo A
    Dig Liver Dis; 2024 Jun; 56(6):964-970. PubMed ID: 38044225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.
    Simsek M; Meijer B; Ramsoekh D; Bouma G; van der Wouden EJ; den Hartog B; de Vries AC; Hoentjen F; Dijkstra G; de Boer SY; Jansen JM; van der Meulen AE; Beukers R; Brink MA; Steinhauser T; Oldenburg B; Gilissen LP; Naber TH; Verhagen MA; de Boer NKH; Mulder CJJ;
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):568-570. PubMed ID: 29775790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease.
    Rulyak SJ; Saunders MD; Lee SD
    J Clin Gastroenterol; 2003 Mar; 36(3):234-7. PubMed ID: 12590235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
    Derijks LJ; de Jong DJ; Gilissen LP; Engels LG; Hooymans PM; Jansen JB; Mulder CJ
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):63-7. PubMed ID: 12544696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.